Rein Therapeutics (RNTX) Interest & Investment Income (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Interest & Investment Income of $18000.0 for Q4 2025, up 125.0% year-over-year from $8000.0 in Q4 2024, and up 50.0% quarter-over-quarter from $12000.0 in Q2 2025.
Rein Therapeutics (RNTX) Interest & Investment Income (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Interest & Investment Income for 10 consecutive years, with $18000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest & Investment Income rose 125.0% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $30000.0 (changed N/A YoY), while the FY2025 annual figure was -$15000.0, down 133.33% from the prior year.
- Interest & Investment Income improved to $18000.0 in Q4 2025 per RNTX's latest filing, from $12000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $50000.0 in Q4 2022 and bottomed at -$62000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $1882.4 across 5 years, with a median of $3000.0 in 2022.
- On a YoY basis, Interest & Investment Income climbed as much as 1400.0% in 2021 and fell as far as 1300.0% in 2021.
- Rein Therapeutics' Interest & Investment Income stood at -$14000.0 in 2021, then soared by 457.14% to $50000.0 in 2022, then plunged by 96.0% to $2000.0 in 2023, then jumped by 300.0% to $8000.0 in 2024, then soared by 125.0% to $18000.0 in 2025.
- Business Quant data shows RNTX's Interest & Investment Income at $18000.0 in Q4 2025, $12000.0 in Q2 2025, and -$45000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | -45,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 50,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | -26,000.00 |
| Mar 31, 2022 | -62,000.00 |
| Dec 31, 2021 | -14,000.00 |
| Sep 30, 2021 | -5,000.00 |
| Jun 30, 2021 | 13,000.00 |
| Mar 31, 2021 | -5,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 1,000.00 |